{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T01:52:56Z","timestamp":1791078776617,"version":"4.1.0"},"reference-count":72,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,12,15]]},"abstract":"<jats:p>One in 20 carriers of human T-cell leukemia virus type 1 (HTLV-1) will develop adult T-cell leukemia\/lymphoma (ATL), a disease frequently associated with hypercalcemia, bone destruction, and a fatal course refractory to current therapies. Overexpression of the HTLV-1\u2013encoded Tax oncoprotein under the human granzyme B promoter causes large granular lymphocytic leukemia\/lymphomas in mice. We found that Tax+ mice spontaneously developed hypercalcemia, high-frequency osteolytic bone metastases, and enhanced osteoclast activity. We evaluated Tax tumors for the production of osteoclast-activating factors. Purification of Tax+ tumor cells and nonmalignant tumor-infiltrating lymphocytes demonstrated that each of these populations expressed transcripts for distinct osteoclast-activating factors. We then evaluated the effect of osteoclast inhibition on tumor formation. Mice doubly transgenic for Tax and the osteoclast inhibitory factor, osteoprotegerin, were protected from osteolytic bone disease and developed fewer soft-tissue tumors. Likewise, osteoclast inhibition with bone-targeted zoledronic acid protected Tax+ mice from bone and soft-tissue tumors and prolonged survival. Tax+ mice represent the first animal model of high-penetrance spontaneous osteolytic bone metastasis and underscore the critical role of nonmalignant host cells recruited by tumor cells in the process of cancer progression and metastasis.<\/jats:p>","DOI":"10.1182\/blood-2005-04-1730","type":"journal-article","created":{"date-parts":[[2005,8,24]],"date-time":"2005-08-24T02:53:26Z","timestamp":1124852006000},"page":"4294-4302","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition"],"prefix":"10.1182","volume":"106","author":[{"given":"Ling","family":"Gao","sequence":"first","affiliation":[{"name":"From the Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis; the Department of Cellular Biology and Physiology, Division of Oncology, Washington University School of Medicine, St Louis; and the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongju","family":"Deng","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis; the Department of Cellular Biology and Physiology, Division of Oncology, Washington University School of Medicine, St Louis; and the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Zhao","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis; the Department of Cellular Biology and Physiology, Division of Oncology, Washington University School of Medicine, St Louis; and the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Hirbe","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis; the Department of Cellular Biology and Physiology, Division of Oncology, Washington University School of Medicine, St Louis; and the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Harding","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis; the Department of Cellular Biology and Physiology, Division of Oncology, Washington University School of Medicine, St Louis; and the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Ratner","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis; the Department of Cellular Biology and Physiology, Division of Oncology, Washington University School of Medicine, St Louis; and the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Weilbaecher","sequence":"additional","affiliation":[{"name":"From the Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis; the Department of Cellular Biology and Physiology, Division of Oncology, Washington University School of Medicine, St Louis; and the Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111817232582700_REF1","doi-asserted-by":"crossref","unstructured":"Ohuchida T, Nishitani H, Kamikawaji N, Niho Y, Ooiwa T, Matsuura K. \u201cAdult T-cell leukemia\/lymphoma\u201d with bone demineralization. Skeletal Radiol. 1985;14: 194-197.","DOI":"10.1007\/BF00355562"},{"key":"2019111817232582700_REF2","doi-asserted-by":"crossref","unstructured":"Weber J. HTLV-1 and tropical spastic paraparesis, 2: the human T-cell lymphotropic virus type 1. Trans R Soc Trop Med Hyg. 1989;83: 729-731.","DOI":"10.1016\/0035-9203(89)90310-6"},{"key":"2019111817232582700_REF3","doi-asserted-by":"crossref","unstructured":"Yamano Y, Nagai M, Brennan M, et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM\/TSP). Blood. 2002;99: 88-94.","DOI":"10.1182\/blood.V99.1.88"},{"key":"2019111817232582700_REF4","doi-asserted-by":"crossref","unstructured":"Ratner L. Adult T cell leukemia lymphoma. Front Biosci. 2004;9: 2852-2859.","DOI":"10.2741\/1442"},{"key":"2019111817232582700_REF5","doi-asserted-by":"crossref","unstructured":"Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol. 1997;15: 15-37.","DOI":"10.1146\/annurev.immunol.15.1.15"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Franchini G, Streicher H. Human T-cell leukaemia virus. Baillieres Clin Haematol. 1995;8: 131-148.","DOI":"10.1016\/S0950-3536(05)80235-5"},{"key":"2019111817232582700_REF7","doi-asserted-by":"crossref","unstructured":"Korber B, Okayama A, Donnelly R, Tachibana N, Essex M. Polymerase chain reaction analysis of defective human T-cell leukemia virus type I proviral genomes in leukemic cells of patients with adult T-cell leukemia. J Virol. 1991;65: 5471-5476.","DOI":"10.1128\/JVI.65.10.5471-5476.1991"},{"key":"2019111817232582700_REF8","doi-asserted-by":"crossref","unstructured":"Azran I, Schavinsky-Khrapunsky Y, Aboud M. Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology. 2004;1: 20-44.","DOI":"10.1186\/1742-4690-1-20"},{"key":"2019111817232582700_REF9","doi-asserted-by":"crossref","unstructured":"Shuh M, Derse D. Ternary complex factors and cofactors are essential for human T-cell leukemia virus type 1 tax transactivation of the serum response element. J Virol. 2000;74: 11394-11397.","DOI":"10.1128\/JVI.74.23.11394-11397.2000"},{"key":"2019111817232582700_REF10","doi-asserted-by":"crossref","unstructured":"Grossman WJ, Ratner L. Transgenic mouse models for HTLV-I infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13(suppl 1): S162-S169.","DOI":"10.1097\/00042560-199600001-00025"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Kehn K, Fuente Cde L, Strouss K, et al. The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene. 2005;24: 525-540.","DOI":"10.1038\/sj.onc.1208105"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Pise-Masison CA, Brady JN. Setting the stage for transformation: HTLV-1 Tax inhibition of p53 function. Front Biosci. 2005;10: 919-930.","DOI":"10.2741\/1586"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Mahieux R, Pise-Masison CA, Nicot C, Green P, Hall WW, Brady JN. Inactivation of p53 by HTLV type 1 and HTLV type 2 Tax trans-activators. AIDS Res Hum Retroviruses. 2000;16: 1677-1681.","DOI":"10.1089\/08892220050193137"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood. 2000;96: 275-281.","DOI":"10.1182\/blood.V96.1.275"},{"key":"2019111817232582700_REF15","doi-asserted-by":"crossref","unstructured":"Ruddle NH, Li CB, Horne WC, et al. Mice transgenic for HTLV-I LTR-tax exhibit tax expression in bone, skeletal alterations, and high bone turnover. Virology. 1993;197: 196-204.","DOI":"10.1006\/viro.1993.1580"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Iwakura Y, Tosu M, Yoshida E, et al. Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science. 1991;253: 1026-1028.","DOI":"10.1126\/science.1887217"},{"key":"2019111817232582700_REF17","doi-asserted-by":"crossref","unstructured":"Saggioro D, Rosato A, Esposito G, et al. Inflammatory polyarthropathy and bone remodeling in HTLV-I Tax-transgenic mice. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14: 272-280.","DOI":"10.1097\/00042560-199703010-00012"},{"key":"2019111817232582700_REF18","doi-asserted-by":"crossref","unstructured":"Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A. 1995;92: 1057-1061.","DOI":"10.1073\/pnas.92.4.1057"},{"key":"2019111817232582700_REF19","doi-asserted-by":"crossref","unstructured":"Mitra-Kaushik S, Harding JC, Hess JL, Ratner L. Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants. Blood. 2004;104: 802-809.","DOI":"10.1182\/blood-2003-11-3967"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood. 2004;104: 3305-3311.","DOI":"10.1182\/blood-2004-01-0266"},{"key":"2019111817232582700_REF21","doi-asserted-by":"crossref","unstructured":"Portis T, Grossman WJ, Harding JC, Hess JL, Ratner L. Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model. J Virol. 2001;75: 2185-2193.","DOI":"10.1128\/JVI.75.5.2185-2193.2001"},{"key":"2019111817232582700_REF22","doi-asserted-by":"crossref","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2: 584-593.","DOI":"10.1038\/nrc867"},{"key":"2019111817232582700_REF23","doi-asserted-by":"crossref","unstructured":"Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer. 1997;80: 1557-1563.","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1557::AID-CNCR5>3.0.CO;2-H"},{"key":"2019111817232582700_REF24","doi-asserted-by":"crossref","unstructured":"Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M. Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor kappaB ligand on adult T-cell leukemia cells. Blood. 2002;99: 634-640.","DOI":"10.1182\/blood.V99.2.634"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1alpha induces hypercalcemia in adult T-cell leukemia. J Bone Miner Res. 2004;19: 1105-1111.","DOI":"10.1359\/JBMR.040314"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Ishibashi K, Ishitsuka K, Chuman Y, et al. Tumor necrosis factor-beta in the serum of adult T-cell leukemia with hypercalcemia. Blood. 1991;77: 2451-2455.","DOI":"10.1182\/blood.V77.11.2451.2451"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Wano Y, Hattori T, Matsuoka M, et al. Interleukin 1 gene expression in adult T cell leukemia. J Clin Invest. 1987;80: 911-916.","DOI":"10.1172\/JCI113152"},{"key":"2019111817232582700_REF28","doi-asserted-by":"crossref","unstructured":"Watanabe T, Yamaguchi K, Takatsuki K, Osame M, Yoshida M. Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be transactivated by HTLV-1 tax gene. J Exp Med. 1990;172: 759-765.","DOI":"10.1084\/jem.172.3.759"},{"key":"2019111817232582700_REF29","doi-asserted-by":"crossref","unstructured":"Liu Y, Dole K, Stanley JR, et al. Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in SCID\/bg and NOD\/SCID mice. Leuk Res. 2002;26: 561-567.","DOI":"10.1016\/S0145-2126(01)00169-2"},{"key":"2019111817232582700_REF30","doi-asserted-by":"crossref","unstructured":"Imada K, Takaori-Kondo A, Sawada H, et al. Serial transplantation of adult T cell leukemia cells into severe combined immunodeficient mice. Jpn J Cancer Res. 1996;87: 887-892.","DOI":"10.1111\/j.1349-7006.1996.tb02116.x"},{"key":"2019111817232582700_REF31","doi-asserted-by":"crossref","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350: 1655-1664.","DOI":"10.1056\/NEJMra030831"},{"key":"2019111817232582700_REF32","doi-asserted-by":"crossref","unstructured":"Choong PF. The molecular basis of skeletal metastases. Clin Orthop. 2003: S19-S31.","DOI":"10.1097\/01.blo.0000093839.72468.da"},{"key":"2019111817232582700_REF33","doi-asserted-by":"crossref","unstructured":"Gallwitz WE, Guise TA, Mundy GR. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest. 2002;110: 1559-1572.","DOI":"10.1172\/JCI0211936"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103: 197-206.","DOI":"10.1172\/JCI3523"},{"key":"2019111817232582700_REF35","doi-asserted-by":"crossref","unstructured":"Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98: 1544-1549.","DOI":"10.1172\/JCI118947"},{"key":"2019111817232582700_REF36","doi-asserted-by":"crossref","unstructured":"Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3: 537-549.","DOI":"10.1016\/S1535-6108(03)00132-6"},{"key":"2019111817232582700_REF37","doi-asserted-by":"crossref","unstructured":"Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer. 2000;88: 2979-2988.","DOI":"10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U"},{"key":"2019111817232582700_REF38","unstructured":"Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988;48: 6876-6881."},{"key":"2019111817232582700_REF39","doi-asserted-by":"crossref","unstructured":"Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH. Animal models of bone metastasis. Cancer. 2003;97: 748-757.","DOI":"10.1002\/cncr.11150"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Winter SF, Cooper AB, Greenberg NM. Models of metastatic prostate cancer: a transgenic perspective. Prostate Cancer Prostatic Dis. 2003;6: 204-211.","DOI":"10.1038\/sj.pcan.4500655"},{"key":"2019111817232582700_REF41","doi-asserted-by":"crossref","unstructured":"Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell. 2004;6: 185-195.","DOI":"10.1016\/j.ccr.2004.07.008"},{"key":"2019111817232582700_REF42","unstructured":"Radl J, Croese JW, Zurcher C, Van den Enden-Vieveen MH, de Leeuw AM. Animal model of human disease: multiple myeloma. Am J Pathol. 1988;132: 593-597."},{"key":"2019111817232582700_REF43","doi-asserted-by":"crossref","unstructured":"Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89: 309-319.","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"2019111817232582700_REF44","doi-asserted-by":"crossref","unstructured":"Parfitt AM. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry of nomenclature committee. J Bone Miner Res. 1987;2: 595-610.","DOI":"10.1002\/jbmr.5650020617"},{"key":"2019111817232582700_REF45","doi-asserted-by":"crossref","unstructured":"Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000;106: 1481-1488.","DOI":"10.1172\/JCI11176"},{"key":"2019111817232582700_REF46","unstructured":"Yu J, Marsh S, Ahluwalia R, McLeod HL. Ferredoxin reductase: pharmacogenomic assessment in colorectal cancer. Cancer Res. 2003;63: 6170-6173."},{"key":"2019111817232582700_REF47","doi-asserted-by":"crossref","unstructured":"Grisolano JL, O'Neal J, Cain J, Tomasson MH. An activated receptor tyrosine kinase, TEL\/PDGFbetaR, cooperates with AML1\/ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci U S A. 2003;100: 9506-9511.","DOI":"10.1073\/pnas.1531730100"},{"key":"2019111817232582700_REF48","doi-asserted-by":"crossref","unstructured":"Lane NE, Yao W, Nakamura MC, et al. Mice lacking the integrin beta5 subunit have accelerated osteoclast maturation and increased activity in the estrogen-deficient state. J Bone Miner Res. 2005;20: 58-66.","DOI":"10.1359\/jbmr.2005.20.1.58"},{"key":"2019111817232582700_REF49","doi-asserted-by":"crossref","unstructured":"Bex F, Gaynor RB. Regulation of gene expression by HTLV-I Tax protein. Methods. 1998;16: 83-94.","DOI":"10.1006\/meth.1998.0646"},{"key":"2019111817232582700_REF50","doi-asserted-by":"crossref","unstructured":"Sohara Y, Shimada H, Minkin C, Erdreich-Epstein A, Nolta JA, DeClerck YA. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res. 2005;65: 1129-1135.","DOI":"10.1158\/0008-5472.CAN-04-2853"},{"key":"2019111817232582700_REF51","doi-asserted-by":"crossref","unstructured":"Anzai S, Takayasu S, Fujiwara S, Tateyama M, Taira H, Takashita M. Elevation of IL-6 in ATL patient with a pathological fracture. J Dermatol. 2002;29: 644-647.","DOI":"10.1111\/j.1346-8138.2002.tb00195.x"},{"key":"2019111817232582700_REF52","doi-asserted-by":"crossref","unstructured":"Mori N, Shirakawa F, Shimizu H, et al. Transcriptional regulation of the human interleukin-6 gene promoter in human T-cell leukemia virus type I-infected T-cell lines: evidence for the involvement of NF-kappa B. Blood. 1994;84: 2904-2911.","DOI":"10.1182\/blood.V84.9.2904.2904"},{"key":"2019111817232582700_REF53","doi-asserted-by":"crossref","unstructured":"Udagawa N, Takahashi N, Akatsu T, et al. The bone marrow-derived stromal cell lines MC3T3-G2\/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology. 1989;125: 1805-1813.","DOI":"10.1210\/endo-125-4-1805"},{"key":"2019111817232582700_REF54","doi-asserted-by":"crossref","unstructured":"Kitazawa R, Kitazawa S. Vitamin D(3) augments osteoclastogenesis via vitamin D-responsive element of mouse RANKL gene promoter. Biochem Biophys Res Commun. 2002;290: 650-655.","DOI":"10.1006\/bbrc.2001.6251"},{"key":"2019111817232582700_REF55","doi-asserted-by":"crossref","unstructured":"Reszka AA, Rodan GA. Bisphosphonate mechanism of action. Curr Rheumatol Rep. 2003;5: 65-74.","DOI":"10.1007\/s11926-003-0085-6"},{"key":"2019111817232582700_REF56","doi-asserted-by":"crossref","unstructured":"Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88: 2961-2978.","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L"},{"key":"2019111817232582700_REF57","doi-asserted-by":"crossref","unstructured":"Croucher PI, De Hendrik R, Perry MJ, et al. Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res. 2003;18: 482-492.","DOI":"10.1359\/jbmr.2003.18.3.482"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16: 593-602.","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Cameron D. Proven efficacy of zoledronic acid in the treatment of bone metastases in patients with breast cancer and other malignancies. Breast. 2003;12(suppl 2): S22-S29.","DOI":"10.1016\/S0960-9776(03)80160-1"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Diel IJ, Kaufmann M, Costa SD, et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst. 1996;88: 1652-1658.","DOI":"10.1093\/jnci\/88.22.1652"},{"key":"2019111817232582700_REF61","doi-asserted-by":"crossref","unstructured":"Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335: 1785-1791.","DOI":"10.1056\/NEJM199612123352401"},{"key":"2019111817232582700_REF62","doi-asserted-by":"crossref","unstructured":"Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20: 3219-3224.","DOI":"10.1200\/JCO.2002.11.080"},{"key":"2019111817232582700_REF63","unstructured":"Arguello F. Metastasis to bone and bone marrow. Cancer Res. 1988;48: 6876-6881."},{"key":"2019111817232582700_REF64","doi-asserted-by":"crossref","unstructured":"Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol. 2002;29: 19-27.","DOI":"10.1053\/sonc.2002.37418"},{"key":"2019111817232582700_REF65","doi-asserted-by":"crossref","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88: 1082-1090.","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z"},{"key":"2019111817232582700_REF66","doi-asserted-by":"crossref","unstructured":"Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol. 2003;14: 1468-1476.","DOI":"10.1093\/annonc\/mdg401"},{"key":"2019111817232582700_REF67","doi-asserted-by":"crossref","unstructured":"Cheng YY, Huang L, Lee KM, Xu JK, Zheng MH, Kumta SM. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int. 2004;75: 71-77.","DOI":"10.1007\/s00223-004-0120-2"},{"key":"2019111817232582700_REF68","doi-asserted-by":"crossref","unstructured":"Mariani S, Muraro M, Pantaleoni F, et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. Leukemia. 2005;19: 664-670.","DOI":"10.1038\/sj.leu.2403693"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Rischer M, Pscherer S, Duwe S, Vormoor J, Jurgens H, Rossig C. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol. 2004;126: 583-592.","DOI":"10.1111\/j.1365-2141.2004.05077.x"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T cell receptor gamma-delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197: 163-168.","DOI":"10.1084\/jem.20021500"},{"key":"2019111817232582700_","doi-asserted-by":"crossref","unstructured":"Wilhelm M, Kunzmann V, Eckstein S, et al. Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102: 200-206.","DOI":"10.1182\/blood-2002-12-3665"},{"key":"2019111817232582700_REF72","doi-asserted-by":"crossref","unstructured":"Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res. 2004;19: 278-288.","DOI":"10.1359\/JBMR.0301230"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/13\/4294\/465228\/zh802405004294.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/13\/4294\/465228\/zh802405004294.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T05:12:04Z","timestamp":1586409124000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/13\/4294\/133283\/HTLV1-Tax-transgenic-mice-develop-spontaneous"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,15]]},"references-count":72,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2005,12,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-04-1730","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,15]]}}}